Lung CancerNCT00460668
The Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life
A study testing pulmonary rehabilitation in people with Lung Cancer and Thoracotomy, run by Isala at 1 site in Netherlands.
Trial summary
The purpose of this study is to evaluate the effects of an integrated multidisciplinary rehabilitation program on health related quality of life in the 12 months postoperative period in patients with an elective thoracotomy and to evaluate the effects of the program on general quality of life (SF-36), acute/chronic… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Lung Cancer, Thoracotomy, Pulmonary Rehabilitation
- What is being tested?
- pulmonary rehabilitation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 57 participants
- Where
- 1 siteNetherlands
- Study dates
- Apr 2007to Sep 2010
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- elective, thoracotomy patients with a surgical intention to cure.
- age between 18 and 80 years.
- ECOG 0 - 2 post-thoracotomy.
Who cannot join
- patients with chronic pain.
- a previous thoracotomy.
- comorbidity limiting rehabilitation.
- non-compliance
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Single Centre Open Randomized Trial on the Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life
The purpose of this study is to evaluate the effects of an integrated multidisciplinary rehabilitation program on health related quality of life in the 12 months postoperative period in patients with an elective thoracotomy and to evaluate the effects of the program on general quality of life (SF-36), acute/chronic post-thoracotomy pain, impairment (changes in pulmonary function), disability (exercise capacity) and start to complete recovery (ECOG score of 0 or 1) 12 months postoperatively in patients with an elective thoracotomy.
Read the detailed description
Morbidity in the post operative phase of thoracotomies is characterised by pain, dyspnea, shoulder dysfunction and a loss of exercise tolerance may occur. There is literature about post-thoracotomy painsyndromes and postoperative quality of life has been investigated. However, data on post-thoracotomy rehabilitation and influence on morbidity and recovery are not available.
Aim of the study:
Primary: To evaluate the effects of an integrated multidisciplinary rehabilitation program on health related quality of life in the 12 months postoperative period in patients with an elective thoracotomy.
Secondary: To evaluate the effects of the program on general quality of life (SF-36), acute/chronic post-thoracotomy pain, impairment (changes in pulmonary function), disability (exercise capacity) and start to complete recovery (ECOG score of 0 or 1) 12 months postoperatively in patients with an elective thoracotomy.
Study design: prospective single-centre, open randomised trial. Eighty-eight elective thoracotomy patients with an age between the 18 and 80 years will be recruited during two years. The follow up for each patient will be one year. The exclusion criteria are chronic pain involvement, a previous thoracotomy, comorbidity limiting rehabilitation, psychiatric illness and non- compliance.
Patients will be asked for participation before thoracotomy by informed consent and will be randomised post-thoracotomy, before discharge into a rehabilitation or 'regular care' group. Randomisation will take place for rehabilitation or regular care by a minimisation program with special attendance to age (< 70 or ≥ 70 years), gender, the result of the 6 minute walk test (< 100 m or ≥ 100 m), the FEV (FEV1< 40% or ≥ FEV1 40 %) and type of surgery (pneumectomy vs other). During screening a spirometry and a 6 minute walk test will be performed. The first questionnaires (VAS, McGill pain questionnaire) will be given to the patients after enrolment and before thoracotomy. The post-thoracotomy pain management consists of the standard analgetic treatment; a thoracic epidural catheter which will be slowly replaced by paracetamol, opioids and NSAID's. The consumption of analgetics will also be documented in the follow up. Supplementary oxygen and lung inhalation is given when necessary. This will be scored too. Regular physical therapy will be started directly after thoracotomy as soon as possible.
The rehabilitation program will be initiated within a month after discharge. The degree of the rehabilitation program will be separately detected for each patient by a cycle test (heart rate) within 3 weeks post-thoracotomy. Patients in the pulmonary rehabilitation program will be guided by a multidisciplinary team of pulmonologist, physical therapist and social worker during 12 weeks. The program will last 3 x 2 hours weekly consisting of exercise training and education.
All patients will be followed up after discharge at 1 month, 3 months, 6 months and 12 months at the outpatient clinic of the pulmonology department and the pain clinic of the anaesthesia department. Before discharge and at these intervals (except for the SGRQ at 1 month), patients have to fill questionnaires about quality of life (SF-36 and SGRQ) and pain (McGill pain questionnaire and VAS). Exercise capacity by means of the 6 minutes walk test and spirometry will be measured after the accomplishment of the rehabilitation program at 3 months.
During follow up all the results between the experimental rehabilitation group and the regular care group will be compared. In the interpretation of these results start to complete recovery is defined as ECOG 0 and 1.
Randomisation, blinding and treatment allocation Randomisation will take place for rehabilitation or regular care by a minimisation program with special attendance to age (< 70 or ≥ 70 years), gender, the result of the 6 minute walk test (< 100 m or ≥ 100 m), the FEV1 (FEV1< 40% or ≥ FEV1 40 %), and type of surgery (pneumectomy vs other).
Study population:
Eighty-eight patients with an elective thoracotomy between the age of 18 and 80 years.
Intervention:
An early pulmonary rehabilitation program during 12 weeks initiated after discharge from the hospital.
Inclusion criteria:
- elective, thoracotomy patients with a surgical intention to cure.
- age between 18 and 80 years.
- ECOG 0 - 2 post-thoracotomy.
Exclusion criteria:
- patients with chronic pain.
- a previous thoracotomy.
- comorbidity limiting rehabilitation.
- non-compliance.
Main study endpoints
- health related quality of life (SGRQ score). Secondary study endpoints
- general quality of life (SF-36).
- acute / chronic post-thoracotomy pain (McGill and VAS).
- impairment (changes in pulmonary function).
- disability (exercise capacity; 6 Minute Walking Distance).
- start to complete recovery (ECOG score of 0 or 1).
Statistical analysis: All analysis will be on an intention-to-treat basis. The primary analysis will be on an intention-to-treat basis. The mean change in the primary endpoint (SGRQ total score) after 6 months between the groups will be analysed using unpaired t-tests. These tests will also be used to analyse differences after 12 months in secondary endpoints (SF-36 scores, 6-minute walking difference, pain scores, and lung function values). Since some study endpoints (quality of life and pain scores) will be measured more than two times (repeatedly measured) the course of these scores in time will be tested using MANOVA-analysis. To test for differences in proportions (proportion of patients with an ECOG-score of 0 or 1 after rehabilitation) the Chi2 -test will be used.
Burden and risks associated with participation:
There are no adverse effects due to the rehabilitation program. Patients in the 'regular care' group will not be guided by the multidisciplinary rehabilitation team. The disadvantages are the following: Patients have to fill in quality of life questionnaires, pain questionnaires and have to evaluate painscales (SGRQ, SF-36; McGill Pain questionnaire and VAS) have to perform the 6 minutes walk-test and a spirometry twice. Finally, patients have to visit the pulmonologist and the pain clinic more frequently. The expected benefits are a better exercise tolerance, less pain and a better quality of life; a faster recovery.
- Conditions
- Lung Cancer, Thoracotomy, Pulmonary Rehabilitation
- Being tested
- pulmonary rehabilitation
- Keywords
- elective thoracotomy, pulmonary rehabilitation, quality of life
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
pulmonary rehabilitationBehavioural
2 or 3 times a week during 8 weeks
| Study group | Role | What they receive |
|---|---|---|
| Pulmonary rehabilitation post-thoracotomy | Experimental | Pulmonary rehabilitation post-thoracotomy Receives: Behavioral: pulmonary rehabilitation |
| Control | No intervention | Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
SGRQ total score
Measured: 12 months
Secondary outcomes (3)
SF-36 scores
Measured: 12 months
McGill pain questionnaire scores
Measured: 12 months
Pulmonary function and 6MWD
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2007 (estimated)
- Study startApr 2007
- Primary completionSep 2010
- Study completionSep 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 57 participants (actual)
Sponsor and investigators
- Lead sponsor
- Isala
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jan W.K. van den Berg, Isala
- Investigators
- J.A. Stigt, Study director, Isala
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00460668
- Sponsor's protocol ID
- NL14089.075.06
- Status last verified
- Apr 2013
- First submitted
- 13 Apr 2007
- Last updated
- 8 Apr 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Single Centre Open Randomized Trial on the Effect of Post-thoracotomy Pulmonary Rehabilitation on Quality of Life
- ClinicalTrials.gov ID
- NCT00460668
- Acronym / sponsor ID
- NL14089.075.06
- Conditions
- Lung Cancer, Thoracotomy, Pulmonary Rehabilitation
- Keywords
- elective thoracotomy, pulmonary rehabilitation, quality of life
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 57 participants (actual)
- Lead sponsor
- IsalaUniversity, hospital or other
- Study start
- Apr 2007
- Primary completion
- Sep 2010 (actual)
- Study completion
- Sep 2010 (actual)
- First posted
- 16 Apr 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the effects of an integrated multidisciplinary rehabilitation program on health related quality of life in the 12 months postoperative period in patients with an elective thoracotomy and to evaluate the effects of the program on general quality of life (SF-36), acute/chronic post-thoracotomy pain, impairment (changes in pulmonary function), disability (exercise capacity) and start to complete recovery (ECOG score of 0 or 1) 12 months postoperatively in patients with an elective thoracotomy.
Detailed description
Morbidity in the post operative phase of thoracotomies is characterised by pain, dyspnea, shoulder dysfunction and a loss of exercise tolerance may occur. There is literature about post-thoracotomy painsyndromes and postoperative quality of life has been investigated. However, data on post-thoracotomy rehabilitation and influence on morbidity and recovery are not available.
Aim of the study:
Primary: To evaluate the effects of an integrated multidisciplinary rehabilitation program on health related quality of life in the 12 months postoperative period in patients with an elective thoracotomy.
Secondary: To evaluate the effects of the program on general quality of life (SF-36), acute/chronic post-thoracotomy pain, impairment (changes in pulmonary function), disability (exercise capacity) and start to complete recovery (ECOG score of 0 or 1) 12 months postoperatively in patients with an elective thoracotomy.
Study design: prospective single-centre, open randomised trial. Eighty-eight elective thoracotomy patients with an age between the 18 and 80 years will be recruited during two years. The follow up for each patient will be one year. The exclusion criteria are chronic pain involvement, a previous thoracotomy, comorbidity limiting rehabilitation, psychiatric illness and non- compliance.
Patients will be asked for participation before thoracotomy by informed consent and will be randomised post-thoracotomy, before discharge into a rehabilitation or 'regular care' group. Randomisation will take place for rehabilitation or regular care by a minimisation program with special attendance to age (< 70 or ≥ 70 years), gender, the result of the 6 minute walk test (< 100 m or ≥ 100 m), the FEV (FEV1< 40% or ≥ FEV1 40 %) and type of surgery (pneumectomy vs other). During screening a spirometry and a 6 minute walk test will be performed. The first questionnaires (VAS, McGill pain questionnaire) will be given to the patients after enrolment and before thoracotomy. The post-thoracotomy pain management consists of the standard analgetic treatment; a thoracic epidural catheter which will be slowly replaced by paracetamol, opioids and NSAID's. The consumption of analgetics will also be documented in the follow up. Supplementary oxygen and lung inhalation is given when necessary. This will be scored too. Regular physical therapy will be started directly after thoracotomy as soon as possible.
The rehabilitation program will be initiated within a month after discharge. The degree of the rehabilitation program will be separately detected for each patient by a cycle test (heart rate) within 3 weeks post-thoracotomy. Patients in the pulmonary rehabilitation program will be guided by a multidisciplinary team of pulmonologist, physical therapist and social worker during 12 weeks. The program will last 3 x 2 hours weekly consisting of exercise training and education.
All patients will be followed up after discharge at 1 month, 3 months, 6 months and 12 months at the outpatient clinic of the pulmonology department and the pain clinic of the anaesthesia department. Before discharge and at these intervals (except for the SGRQ at 1 month), patients have to fill questionnaires about quality of life (SF-36 and SGRQ) and pain (McGill pain questionnaire and VAS). Exercise capacity by means of the 6 minutes walk test and spirometry will be measured after the accomplishment of the rehabilitation program at 3 months.
During follow up all the results between the experimental rehabilitation group and the regular care group will be compared. In the interpretation of these results start to complete recovery is defined as ECOG 0 and 1.
Randomisation, blinding and treatment allocation Randomisation will take place for rehabilitation or regular care by a minimisation program with special attendance to age (< 70 or ≥ 70 years), gender, the result of the 6 minute walk test (< 100 m or ≥ 100 m), the FEV1 (FEV1< 40% or ≥ FEV1 40 %), and type of surgery (pneumectomy vs other).
Study population:
Eighty-eight patients with an elective thoracotomy between the age of 18 and 80 years.
Intervention:
An early pulmonary rehabilitation program during 12 weeks initiated after discharge from the hospital.
Inclusion criteria:
- elective, thoracotomy patients with a surgical intention to cure.
- age between 18 and 80 years.
- ECOG 0 - 2 post-thoracotomy.
Exclusion criteria:
- patients with chronic pain.
- a previous thoracotomy.
- comorbidity limiting rehabilitation.
- non-compliance.
Main study endpoints
- health related quality of life (SGRQ score). Secondary study endpoints
- general quality of life (SF-36).
- acute / chronic post-thoracotomy pain (McGill and VAS).
- impairment (changes in pulmonary function).
- disability (exercise capacity; 6 Minute Walking Distance).
- start to complete recovery (ECOG score of 0 or 1).
Statistical analysis: All analysis will be on an intention-to-treat basis. The primary analysis will be on an intention-to-treat basis. The mean change in the primary endpoint (SGRQ total score) after 6 months between the groups will be analysed using unpaired t-tests. These tests will also be used to analyse differences after 12 months in secondary endpoints (SF-36 scores, 6-minute walking difference, pain scores, and lung function values). Since some study endpoints (quality of life and pain scores) will be measured more than two times (repeatedly measured) the course of these scores in time will be tested using MANOVA-analysis. To test for differences in proportions (proportion of patients with an ECOG-score of 0 or 1 after rehabilitation) the Chi2 -test will be used.
Burden and risks associated with participation:
There are no adverse effects due to the rehabilitation program. Patients in the 'regular care' group will not be guided by the multidisciplinary rehabilitation team. The disadvantages are the following: Patients have to fill in quality of life questionnaires, pain questionnaires and have to evaluate painscales (SGRQ, SF-36; McGill Pain questionnaire and VAS) have to perform the 6 minutes walk-test and a spirometry twice. Finally, patients have to visit the pulmonologist and the pain clinic more frequently. The expected benefits are a better exercise tolerance, less pain and a better quality of life; a faster recovery.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pulmonary rehabilitation post-thoracotomy | Experimental | Behavioral: pulmonary rehabilitationPulmonary rehabilitation post-thoracotomy |
| Control | No intervention | –Control |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- elective, thoracotomy patients with a surgical intention to cure.
- age between 18 and 80 years.
- ECOG 0 - 2 post-thoracotomy.
Key exclusion criteria (4 listed)
- patients with chronic pain.
- a previous thoracotomy.
- comorbidity limiting rehabilitation.
- non-compliance
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| pulmonary rehabilitation2 or 3 times a week during 8 weeks | Behavioural | Pulmonary rehabilitation post-thoracotomy |
Primary outcome
SGRQ total score
Time frame: 12 months
3 secondary outcomes
SF-36 scores
Time frame: 12 months
McGill pain questionnaire scores
Time frame: 12 months
Pulmonary function and 6MWD
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2013.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
J.A. Stigt study director
Isala
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing pulmonary rehabilitation in people with Lung Cancer and Thoracotomy, run by Isala at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SGRQ total score (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2013.